Encephalitis associated with glutamic acid decarboxylase autoantibodies in a child: A treatable condition?

Archives of Neurology

Volumn 68, Issue 8, 2011, Pages 1065-1068

  Korff, Christian M ^a   Parvex, Paloma ^a   Cimasoni, Laurent ^a   Wilhelm Bals, Alexandra ^a   Hampe, Christiane S ^b   Schwitzgebel, Valerie M ^a   Michel, Meĺanie ^a   Siegrist, Claire Anne ^a   Lalive, Patrice H ^a   Seeck, Margitta ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CLOBAZAM; GLUTAMATE DECARBOXYLASE ANTIBODY; IMMUNOGLOBULIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; PYRIDOXINE; RITUXIMAB; STIRIPENTOL; THIAMINE; TOPIRAMATE; UBIDECARENONE;

ARTICLE; BLOOD ANALYSIS; CASE REPORT; CEREBROSPINAL FLUID; CHILD; DISEASE ASSOCIATION; ELECTROENCEPHALOGRAM; ENCEPHALITIS; ENZYME ACTIVITY; FEMALE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; KETOGENIC DIET; LUMBAR PUNCTURE; NUCLEAR MAGNETIC RESONANCE IMAGING; PLASMAPHERESIS; POSITRON EMISSION TOMOGRAPHY; PRESCHOOL CHILD; PRIORITY JOURNAL; REMISSION; SEIZURE;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTICONVULSANTS; ANTIRHEUMATIC AGENTS; AUTOANTIBODIES; CHILD; ENCEPHALITIS; EPILEPSY; FEMALE; GAMMA-AMINOBUTYRIC ACID; GLUTAMATE DECARBOXYLASE; HUMANS; PLASMAPHERESIS;

EID: 80051559277     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneurol.2011.177     Document Type: Article

References (23)

1. Saiz A, Blanco Y, Sabater L, et al. Spectrum of neurological syndromes associated with glutamic acid decarboxylase antibodies: diagnostic clues for this association. Brain. 2008;131(pt 10):2553-2563.
2. Liimatainen S, Peltola M, Sabater L, et al. Clinical significance of glutamic acid decarboxylase antibodies in patients with epilepsy. Epilepsia. 2009;51(5):760-767.
3. Olson JA, Olson DM, Sandborg C, Alexander S, Buckingham B. Type 1 diabetes mellitus and epilepsia partialis continua in a 6-year-old boy with elevated anti-GAD65 antibodies. Pediatrics. 2002;109(3):e50. doi:10.1542/peds.109.3.e50.
4. Akman CI, Patterson MC, Rubinstein A, Herzog R. Limbic encephalitis associated with anti-GAD antibody and common variable immune deficiency. Dev Med Child Neurol. 2009;51(7):563-567.
5. Hampe CS, Hammerle LP, Bekris L, et al. Recognition of glutamic acid decarboxylase (GAD) by autoantibodies from different GAD antibody-positive phenotypes. J Clin Endocrinol Metab. 2000;85(12):4671-4679. (Pubitemid 32157650)
6. Mire-Sluis A, Gaines Das R, Lernmark A. Standardization of antibody preparations for use in immunogenicity studies: a case study using the World Health Organization International Collaborative Study for Islet Cell Antibodies. Dev Biol (Basel). 2003;112:153-163.
7. Padoa CJ, Banga JP, Madec AM, et al. Recombinant Fabs of human monoclonal antibodies specific to the middle epitope of GAD65 inhibit type 1 diabetes-specific GAD65Abs. Diabetes. 2003;52(11):2689-2695. (Pubitemid 37339698)
8. Tremble J, Morgenthaler NG, Vlug A, et al. Human B cells secreting immunoglobulin G to glutamic acid decarboxylase-65 from a nondiabetic patient with multiple autoantibodies and Graves' disease: a comparison with those present in type 1 diabetes. J Clin Endocrinol Metab. 1997;82(8):2664-2670. (Pubitemid 27337890)
9. Fenalti G, Hampe CS, Arafat Y, et al. COOH-terminal clustering of autoantibody and T-cell determinants on the structure of GAD65 provide insights into the molecular basis of autoreactivity. Diabetes. 2008;57(5):1293-1301.
10. Hampe CS, Hammerle LP, Falorni A, Robertson J, Lernmark A. Site-directed mutagenesis of K396R of the 65 kDa glutamic acid decarboxylase active site obliterates enzyme activity but not antibody binding. FEBS Lett. 2001;488(3):185-189. (Pubitemid 32106653)
11. Vincent A, Dale RC. Autoimmune channelopathies and other antibody-associated neurological disorders. In: Dale RC, Vincent A, eds. Inflammatory and Autoimmune Disorders of the Nervous System in Children. London, England: MacKeith Press; 2010:365-387. Clinics in Developmental Medicine, No. 184-185.
12. B-receptor-mediated synaptic responses by autoantibodies to glutamic acid decarboxylase. J Neurol Sci. 2003;208(1-2):51-56.
13. Stagg CJ, Lang B, Best JG, et al. Autoantibodies to glutamic acid decarboxylase in patients with epilepsy are associated with low cortical GABA levels. Epilepsia. 2010;51(9):1898-1901.
14. Vianello M, Keir G, Giometto B, Betterle C, Tavolato B, Thompson EJ. Antigenic differences between neurological and diabetic patients with anti-glutamic acid decarboxylase antibodies. Eur J Neurol. 2005;12(4):294-299. (Pubitemid 40480981)
15. Dinkel K, Rickert M, Möller G, Adamski J, Meinck HM, Richter W. Stiff-man syndrome: identification of 17β-hydroxysteroid dehydrogenase type 4 as a novel 80-kDa antineuronal antigen. J Neuroimmunol. 2002;130(1-2):184- 193. (Pubitemid 35240006)
16. Daw K, Ujihara N, Atkinson M, Powers AC. Glutamic acid decarboxylase autoantibodies in stiff-man syndrome and insulin-dependent diabetes mellitus exhibit similarities and differences in epitope recognition. J Immunol. 1996;156(2):818-825. (Pubitemid 26028943)
17. Raju R, Foote J, Banga JP, et al. Analysis of GAD65 autoantibodies in stiff-person syndrome patients. J Immunol. 2005;175(11):7755-7762. (Pubitemid 41715229)
18. Malter MP, Helmstaedter C, Urbach H, Vincent A, Bien CG. Antibodies to glutamic acid decarboxylase define a form of limbic encephalitis. Ann Neurol. 2010;67(4):470-478.
19. Dalakas MC. B cells as therapeutic targets in autoimmune neurological disorders. Nat Clin Pract Neurol. 2008;4(10):557-567.
20. Zecca M, Nobili B, Ramenghi U, et al. Rituximab for the treatment of refractory autoimmune hemolytic anemia in children. Blood. 2003;101(10):3857- 3861. (Pubitemid 36857857)
21. Albaramki JH, Teo J, Alexander SI. Rituximab therapy in two children with autoimmune thrombotic thrombocytopenic purpura. Pediatr Nephrol. 2009;24(9):1749-1752.
22. Binstadt BA, Caldas AM, Turvey SE, et al. Rituximab therapy for multisystem autoimmune diseases in pediatric patients. J Pediatr. 2003;143(5):598-604. (Pubitemid 37452785)
23. Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H, et al; Type 1 Diabetes Trial-Net Anti-CD20 Study Group. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med. 2009;361(22):2143-2152.